

Susvimo® (ranibizumab intravitreal injection via ocular implant)

When requesting Susvimo® (ranibizumab intravitreal injection via ocular implant), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines

FDA-approved indication

Susvimo is indicated for the treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor medication.

Coverage Guidelines

Due to safety concerns, approval is not recommended for Susvimo. There are significant risks of use based on the Boxed Warning regarding endophthalmitis.

References

1. Susvimo™ intravitreal injection via ocular implant [prescribing information]. South San Francisco, CA: Genentech/Roche; April 2022.
2. Holekamp NM, Campochiaro PA, Chang M, et al; Archway Investigators. Archway randomized phase III trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. *Ophthalmology*. 2021 Sep 28. [Epub ahead of print].
3. Awh CC, on behalf of the Archway Investigators. Updated safety and efficacy results from the Archway Phase III trial of the port delivery system with ranibizumab (PDS) for neovascular AMD. Presented at: the American Society of Retina Specialists 39th Annual Meeting; San Antonio, TX; October 8-12, 2021.